Companies /Healthcare
Recursion Pharmaceuticals Inc - Class A
NASDAQ: RXRX Biotechnology
$3.47
▼ $0.41 (−10.57%) today
Markets open · 1:55pm ET

Recursion Pharmaceuticals (RXRX) Q3 2026 Earnings

Reported Nov 2, 2026, 4:32pm ET · SEC source
$-0.22
Beat +3.85%
EPS · est. $-0.23 GAAP

Quarter includes a $10.0 million Sanofi milestone payment recognized in collaboration revenue; prior-year quarter included $22.8 million of in-process R&D costs for REC-102 that did not recur.

$18.6M
Beat +25.25%
Revenue · est. $14.8M
1 quarter
Consecutive EPS beats

How Did RXRX Stock React to Q3 2026 Earnings?

% change · around the report
−3%0+3%+6%Nov 2Nov 3report 4:32pm ETearnings−0.2%−3.6%
−3%0+3%+6%Nov 2Nov 3earnings−0.2%−3.6%
RXRX −3.6%S&P 500 −0.2%
−3%0+3%+6%Nov 2Nov 3report 4:32pm ETearnings−0.2%−3.6%
−3%0+3%+6%Nov 2Nov 3earnings−0.2%−3.6%
RXRX −3.6%NASDAQ −0.2%
−10%−5%0+5%Nov 2Nov 5report 4:32pm ETearnings−2.3%−9.5%
−10%−5%0+5%Nov 2Nov 5earnings−2.3%−9.5%
RXRX −9.5%S&P 500 −2.3%
−10%−5%0+5%Nov 2Nov 5report 4:32pm ETearnings−4.7%−9.5%
−10%−5%0+5%Nov 2Nov 5earnings−4.7%−9.5%
RXRX −9.5%NASDAQ −4.7%
−4.96%
Day of report
−3.92%
Next session

Did RXRX Beat Earnings? Q3 2026 Results

Yes. Recursion Pharmaceuticals reported Q3 2026 earnings of $-0.22 a share on Nov 2, 2026, beating the $-0.23 consensus estimate by 3.8%. Revenue was $18.6M against a $14.8M estimate.

Recursion Pharmaceuticals delivered a stronger-than-expected third quarter of 2026, beating on both the top and bottom lines as partnership momentum and sharply lower costs narrowed its losses. The company reported GAAP EPS of negative $0.22, a 3.85% beat against the consensus estimate of negative $0.23; that figure reflects the one-time benefit of a $10.00 million Sanofi milestone payment recognized in collaboration revenue, while the year-ago quarter carried $22.80 million in in-process R&D charges tied to the REC-102 acquisition that did not recur. Revenue surged 258.5% year over year to $18.55 million, clearing the $14.81 million consensus by 25.25%, with the Sanofi payment the primary driver after the partner optioned Recursion's first immunology development candidate and plans to advance it into Phase 1 in 2027. An October equity raise lifted pro forma cash to roughly $748.70 million, extending the runway into 2029, while the company reiterated 2026 cash operating expense guidance below $375.00 million and set a 2027 target below $360.00 million.

Key Takeaways
  • Revenue increase driven primarily by Sanofi collaboration, including a $10.0 million milestone for an immunology small molecule program
  • R&D expense decreased mainly due to non-recurrence of $22.8 million in-process R&D costs for REC-102 recognized in Q3 2025
  • G&A decreased due to lower infrastructure technology expenses and professional service costs
  • Operating cash use declined on operating efficiencies and working capital movements

“The new TUPELO data are important clinical evidence, with REC-4881 showing deep polyp burden reductions across the upper and lower GI tract, including larger, higher-risk polyps, and reductions that persist after treatment stops. REC-1245 is an encouraging early example of that engine coming together within a single program, from biological insight surfaced by our platform to molecule design and now early clinical signals in heavily pretreated patients.”

Recursion Pharmaceuticals CEO, on the earnings call

What Is Recursion Pharmaceuticals's Outlook?

Recursion expects its cash runway to extend into 2029 based on current operating plans with no additional financing, including roughly $187.2 million of net proceeds from its October 2026 offering. It reiterated 2026 cash operating expense guidance of less than $375 million and set 2027 guidance of less than $360 million. Expected program milestones: - **REC-4881:** registrational trial anticipated in 2H27, pending ongoing FDA discussions, with more details later this year. - **REC-1245:** preliminary endometrial cancer dose-expansion data expected in 2H27, with dose escalation continuing in other solid tumors. - **Sanofi-optioned immunology candidate:** expected to enter Phase 1 in 2027. - **Sanofi collaboration:** additional programs could reach development candidate and other milestones over the next 12 months. - **Genentech:** the first neuroscience target will advance through small molecule design and hit generation.

RXRX YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$-100,000,000$-50,000,000$0$5.2M$18.6MRevenue$-95,879,194$-123,176,000Operating Income$-93,995,578$-119,036,000Net Income
$-100,000,000$-50,000,000$0RevenueOperating IncomeNet Income
RXRX income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $18.6M $5.2M +258.5%
Operating Income −$123.2M −$95.9M +28.5%
Net Income −$119.0M −$94.0M +26.6%

RXRX Revenue by Segment

Collaboration Operating Revenue$18.1M
Grant Revenue$497,000

Figures from SEC filings and company reports. Not investment advice.